<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078516</url>
  </required_header>
  <id_info>
    <org_study_id>N-20190003</org_study_id>
    <nct_id>NCT04078516</nct_id>
  </id_info>
  <brief_title>Methods of Early Detection and Grading Of Diabetic Peripheral Neuropathy (MEDON)</brief_title>
  <acronym>MEDON</acronym>
  <official_title>Perception Threshold Tracking(PTT): A Novel Method for Early Detection and Grading of Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MEDON aims to examine new methods for early detection and grading of diabetic peripheral
      neuropathy focusing on both small- and large nerve fibers. Furthermore, MEDON aims to
      describe differences between people with classic diabetic peripheral neuropathy and those
      with painful diabetic neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of CCM, PTT, AF and MRI</measure>
    <time_frame>End of study (when all patients have completed all sessions. Latest 31. december 2021)</time_frame>
    <description>Using Quantitative Sensory Testing (small fibers) and conventional nerve conduction studies (large fibers) as golden standards, we will determine the prognostic value of:
Perception Threshold Tracking Corneal Confocal Microscopy Axon-flair mediated response MRI-scans in detecting neuropathy. Sensitivity and specificity will be reported.
OBS! Tests will be tested in the initial groups and AFTER a group re-arrangement based on results from QST and NCS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of PainDETECT in diabetes</measure>
    <time_frame>End of study / end of inclusion (when all patients have completed the screening session. Latest 31. november 2021)</time_frame>
    <description>Correlation between PainDETECT and DN4 will be reported.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory measures</measure>
    <time_frame>End of study (latest december 31 2021).</time_frame>
    <description>An multi-variant analysis to determine the predictive ability of combinations of primary outcome measures.</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuropathy, Diabetic</condition>
  <condition>Neuropathy, Painful</condition>
  <arm_group>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <description>No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <description>No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <description>No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <description>No interventions. A series of observationel/expirimental methods for detecting and grading neuropathy will be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Perception Threshold Tracking (PTT)</intervention_name>
    <description>low-current electrical stimulation of both large- and small nerve fibers.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Axon-flair mediated respons</intervention_name>
    <description>Laser-doppler examination of small blood vessels in the peripheral skin.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <other_name>Laser-doppler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Heart rate variability</intervention_name>
    <description>4 measurements of heart rate.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <other_name>Vagus TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative Sensory Testing (QST)</intervention_name>
    <description>Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <other_name>German Research Network on Neuropathic Pain (DFNS) standard protocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Peripheral blood pressure and transcutaneous oxygen tension</intervention_name>
    <description>Ankle/brachial index, toe/brachial index, TcpO2.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <other_name>Perimed 6000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires for detecting painful neuropathy</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
    <other_name>PainDETECT, Douleur Neuropathique 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Corneal Confocal Microscopy /CCM)</intervention_name>
    <description>Confocal microscopy of the cornea measuring NBD, NFD, NFL</description>
    <arm_group_label>Matched controls without diabetes</arm_group_label>
    <arm_group_label>Type 1 diabetes and no neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and non-painful neuropathy</arm_group_label>
    <arm_group_label>Type 1 diabetes and painful neuropathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population include four well-defined groups of subjects:

          1. Patients with Type 1 diabetes and painful diabetic peripheral neuropathy (DPN).

          2. Patients with Type 1 diabetes and non-painful diabetic peripheral neuropathy (DPN)

          3. Patients with Type 1 diabetes and without diabetic peripheral neuropathy (VPT&lt;15)
             (DPN).

          4. Healthy control subjects matched for age, BMI, and gender. Diabetes duration, HbA1c,
             insulin use, ethnicity, and co-morbidities will be matched between group 1, 2 and 3 to
             best ability.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women minimum 18 years of age and maximum 75 years of age

          2. Signed informed consent form

          3. Diagnosed with diabetes type I (for group 1-3)

          4. Diagnosed with DPN defined as a threshold above 25-volt biothesiometry or absent
             feeling on the big toe using 10g-monofilament. (for group 1-2)

          5. Answered questionnaire: PainDETECT

          6. Nothing abnormal on initial tests (group 4)

          7. Accepted initial screening blood samples

          8. MRI-compatible participant

        Exclusion Criteria:

          -  1. Current or previous alcohol- or drug abuse 2. Abnormal screening blood samples 3.
             Not being able to understand Danish written and/or verbally 4. Not being able to
             corporate to examination (e.g. not being able to speak, suffering from senile dementia
             etc.) 5. Previous chemotherapy or intake of experimental medicine 6. Active HSV- or
             VZV-infection or known HIV 7. Known severe skin disease 8. Known neural damage or
             disease in the neural system (e.g. MS, Guillain-Barre etc.) 9. Critical limb ischemia
             defined as in current clinical consensus 10. Allergy or intolerance to histamine or
             inability to make do without for one day 11. Pregnancy 12. Active cancer-disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Ejskjær, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabtes Center North Denmark, Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels Ejskjær, Professor</last_name>
    <phone>9766365</phone>
    <phone_ext>+45</phone_ext>
    <email>n.ejskjaer@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johan B Røikjer, MD</last_name>
    <phone>97663651</phone>
    <phone_ext>+45</phone_ext>
    <email>j.roeikjaer@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>North Denmark</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Ejskjær, MD,Professor</last_name>
      <phone>97663656</phone>
      <email>n.ejskjaer@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Johan B Røikjer, MD</last_name>
      <phone>97663651</phone>
      <email>j.roeikjaer@rn.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Niels Ejskjær</investigator_full_name>
    <investigator_title>Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>neuropathy</keyword>
  <keyword>early detection</keyword>
  <keyword>small nerve fibers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with collaborating department: Department of Radiology with the purpose of analyzing the data and comparing it to their MRI scans.
Data will be shared with Aalborg University with the purpose of analyzing data.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>During and after the study. Data will be available no longer than needed for analyzing.</ipd_time_frame>
    <ipd_access_criteria>anonymized data</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT04078516/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

